New pill HRS-2129 aims to ease knee arthritis pain
NCT ID NCT07351968
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called HRS-2129 in 200 people with moderate to severe knee osteoarthritis pain. Participants will receive either HRS-2129, a placebo, or an active comparator (celecoxib) to see if it reduces pain and improves joint function. The study is double-blind, meaning neither patients nor doctors know who gets what, to ensure unbiased results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-2129 tablet
What this could lead to
If successful, this could lead to a new pain relief option for people with knee osteoarthritis.
What could go wrong
This is an early Phase 1 study with only 200 people, so it's too soon to know if HRS-2129 works or is safe. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AND SEVERE PAIN IN KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Drum Tower Hospital affiliated to Nanjing University School of Medicine
RECRUITINGNanjing, Jiangsu, 210005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact